Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Richard John Daly M.B.A. | President, CEO & Director | 68.12k | -- | 1961 |
| Dr. Steven R. Miller Ph.D. | Executive VP, COO & Chief Scientific Officer | 884.7k | -- | 1962 |
| Dr. Gary Ingenito M.D., Ph.D. | Chief Medical & Regulatory Officer | 811.39k | -- | 1956 |
| Mr. Jeffrey Del Carmen | Executive VP & Chief Commercial Officer | 799.82k | -- | 1971 |
| Mr. Michael W. Kalb CPA | Executive VP, Treasurer & CFO | -- | -- | 1971 |
| Ms. Mary Coleman | VP & Head of Investor Relations | -- | -- | -- |
| Mr. Brian Elsbernd J.D. | Chief Compliance Officer & Chief Legal Officer | 311.42k | -- | 1964 |
| Mr. Pete Curry Sr. | Vice President of Sales | -- | -- | -- |
| Dr. Stanley Iyadurai M.D., Ph.D. | Senior Vice President of Medical Affairs & Drug Discovery | -- | -- | -- |
| Dr. Preethi Sundaram Ph.D. | Chief Strategy Officer | 511.25k | -- | 1976 |
Catalyst Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 167
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Corporate Governance
Upcoming Events
February 26, 2025 at 9:00 PM UTC - March 3, 2025 at 9:00 PM UTC
Catalyst Pharmaceuticals, Inc. Earnings Date
Recent Events
November 4, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
September 5, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission